Cross-resistance within the protease inhibitor class
Race, E.
Antiviral Therapy 6(Suppl 2): 29-36
2001
ISSN/ISBN: 1359-6535 PMID: 11678476 Document Number: 535609
Document emailed within 1 workday
Related Documents
Ala, P.J.; Rodgers, J.D.; Chang, C.H. 1999: HIV protease drug resistance and its impact on inhibitor design Current Opinion in Drug Discovery and Development 2(4): 265-273Taiwo, B.O.; Hicks, C.B. 2007: Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistance Aids Reader 17(3): 151-156; 159-161
Gaillard, M.C.; Reichberg, S.B.; Nogueira, C.M.; Kilroe-Smith, T.A. 1993: Differences in elastase-binding activity of alpha 1-protease inhibitor and alpha 2-macroglobulin for asthma patients and control subjects with various alpha 1-protease inhibitor phenotypes Clinical Chemistry 39(4): 675-679
Marcelin, A.-G.; Flandre, P.; de Mendoza, C.; Roquebert, B.; Peytavin, G.; Valer, L.; Wirden, M.; Abbas, S.; Katlama, C.; Soriano, V.; Calvez, V. 2007: Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients Antiviral Therapy 12(2): 247-252
Czernicki, Z. 1977: Effect of agents increasing the resistance of the vascular wall as well as of trasylol (a protease inhibitor) on experimental brain edema Neurologia i Neurochirurgia Polska 11(4): 457-460
Taylor, B.S.; Hunt, G.; Abrams, E.J.; Coovadia, A.; Meyers, T.; Sherman, G.; Strehlau, R.; Morris, L.; Kuhn, L. 2011: Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa AIDS research and human retroviruses 27(9): 945-956
Traber, D.L.; Adams, T.; Sziebert, L.; Williams, P.; Traber, L.D. 1984: Failure of a protease inhibitor to affect the cardiopulmonary response to endotoxin when combined with a cyclooxygenase inhibitor Circulatory Shock 13(4): 319-323
Della Porta, P.; Soeltl, R.; Krell, H.W.; Collins, K.; O'Donoghue, M.; Schmitt, M.; Krüger, A. 1999: Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo Anticancer Research 19(5b): 3809-3816
Courcambeck, J.ér.ôm.; Bouzidi, M.; Perbost, R.ég.; Jouirou, B.; Amrani, N.; Cacoub, P.; Pèpe, G.ér.; Sabatier, J.-M.; Halfon, P. 2006: Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations Antiviral Therapy 11(7): 847-855
Piliero, P.J. 2004: Atazanavir: A novel once-daily protease inhibitor Drugs of Today 40(11): 901-912
Besson, C.; Jubault, V.; Viard, J.P.; Pialoux, G. 1998: Ketoacidosis associated with protease inhibitor therapy Aids 12(11): 1399-1400
Cabot de Vega, E.; Fontecha Gómez, B.J.; Solé Arnau, R.; Pedrol Clotet, E. 1999: Peripheral lipodystrophy associated with protease inhibitor therapy Revista Clinica Espanola 199(8): 546-547
Bierl, H. 2003: Atazanavir--first protease inhibitor for one dose administration Deutsche Medizinische Wochenschrift 128(39): 2039-2040
Buch, H.J. 1970: Treatment of arthrosis with protease-inhibitor Contrykal Das Deutsche Gesundheitswesen 25(20): 947-950
Juhász, S. 1983: Studies on the protease inhibitor of Klebsiella aerogenes Acta Veterinaria Hungarica 31(4): 121-123
Viciana, P.; Miralles-Martín, P.; Knobel, H.; Gatell, J.M. 1998: Prevention of opportunistic infections in the protease inhibitor era Enfermedades Infecciosas y Microbiologia Clinica 16 Suppl. 1: 1-10
Gastaldi, G.; Mattiello, A. 1971: Effect of a protease inhibitor on bacterial multiplication Pathologica 63(923): 223-231
Eftekhari, N.; Ward, A.M.; Allen, R.; Greaves, M.W. 1980: Protease inhibitor profiles in urticaria and angio-oedema British Journal of Dermatology 103(1): 33-39
Nigro, L.; Romano, F.; Tosto, S.; Zagami, A.; Bruno, S.; Nunnari, A. 1999: Severe hepatitis in a HIV-positive subject under treatment with protease inhibitor Italian Journal of Gastroenterology and Hepatology 31(1): 85-86
Ohkoshi, M.; Sasaki, Y. 2005: Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan) In Vivo 19(1): 133-136